President and executive director Li Yeqing increased his stake in Huaxin Building Materials Group (06655) by purchasing 8500 shares at a unit price of 16.797 Hong Kong dollars.
On December 4th, President and Executive Director Li Yeqing increased his holdings in Huaxin Cement (06655) by 8500 shares, priced at 16.797 Hong Kong dollars per share, with a total amount of approximately 142,800 Hong Kong dollars.
The latest information from the Hong Kong Stock Exchange shows that on December 4th, President and Executive Director Li Yeqing increased his holdings of Huaxin Building Materials Group (06655) by 8,500 shares at a price of 16.797 Hong Kong dollars per share, with a total amount of approximately 142,800 Hong Kong dollars. After the increase, the latest number of shares held is approximately 1.1386 million shares, with a latest shareholding percentage of 0.15%.
Related Articles
HK Stock Market Move | Metallurgical Corporation of China (01618) opens down nearly 6%, planning to sell its assets including China Metallurgical Group and China Metallurgical Copper-Zinc for 60.7 billion yuan.
HK Stock Market Move | CONCORD HC GP(02453) opened more than 6%, its subsidiary Guangzhou Taihe Cancer Hospital has been approved to enter the list of designated medical institutions of "Hong Kong and Macao Medical Devices Pass"
HK Stock Market Move | ASCLETIS-B (01672) opened nearly 15% higher. Positive topline results were obtained from the 13-week Phase II study of ASC30 for the treatment of obesity.
HK Stock Market Move | Metallurgical Corporation of China (01618) opens down nearly 6%, planning to sell its assets including China Metallurgical Group and China Metallurgical Copper-Zinc for 60.7 billion yuan.
HK Stock Market Move | CONCORD HC GP(02453) opened more than 6%, its subsidiary Guangzhou Taihe Cancer Hospital has been approved to enter the list of designated medical institutions of "Hong Kong and Macao Medical Devices Pass"
HK Stock Market Move | ASCLETIS-B (01672) opened nearly 15% higher. Positive topline results were obtained from the 13-week Phase II study of ASC30 for the treatment of obesity.
RECOMMEND
Baidu’s AI Ace Kunlunxin Prepares For Hong Kong IPO, Domestic Computing Power Faces Crucial Test
08/12/2025
Institutions Say Short-Term Volatility Does Not Alter Upward Trend Of Hong Kong Stocks, Hang Seng Index Still Expected To Challenge 30,000 Points Next Year
08/12/2025
As The 2025 Central Economic Work Conference Approaches, What New Expectations Lie Ahead For Next Year’s Economic Agenda? Institutions Forecast Five Key Highlights
08/12/2025
